CA3238868A1 - Anti-sost antibody pharmaceutical composition and use thereof - Google Patents

Anti-sost antibody pharmaceutical composition and use thereof Download PDF

Info

Publication number
CA3238868A1
CA3238868A1 CA3238868A CA3238868A CA3238868A1 CA 3238868 A1 CA3238868 A1 CA 3238868A1 CA 3238868 A CA3238868 A CA 3238868A CA 3238868 A CA3238868 A CA 3238868A CA 3238868 A1 CA3238868 A1 CA 3238868A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
antibody
seq
concentration
sost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3238868A
Other languages
English (en)
French (fr)
Inventor
Shuang SHAN
Chenmin TIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3238868A1 publication Critical patent/CA3238868A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3238868A 2021-11-30 2022-11-30 Anti-sost antibody pharmaceutical composition and use thereof Pending CA3238868A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111462784.6 2021-11-30
CN202111462784 2021-11-30
PCT/CN2022/135247 WO2023098694A1 (zh) 2021-11-30 2022-11-30 一种抗sost抗体药物组合物及其用途

Publications (1)

Publication Number Publication Date
CA3238868A1 true CA3238868A1 (en) 2023-06-08

Family

ID=86611532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3238868A Pending CA3238868A1 (en) 2021-11-30 2022-11-30 Anti-sost antibody pharmaceutical composition and use thereof

Country Status (8)

Country Link
US (1) US20250011411A1 (enExample)
EP (1) EP4434517A4 (enExample)
JP (1) JP2024543931A (enExample)
CN (1) CN118175993A (enExample)
AU (1) AU2022401939A1 (enExample)
CA (1) CA3238868A1 (enExample)
TW (1) TW202330032A (enExample)
WO (1) WO2023098694A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
HK1200322A1 (en) * 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against sclerostin
SI3269735T1 (sl) 2015-03-13 2020-12-31 Jiangsu Hengrui Medicine Co. Ltd. Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN109952093B (zh) 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
EP4013786A1 (en) * 2019-08-12 2022-06-22 Amgen Inc. Anti-sclerostin antibody formulations

Also Published As

Publication number Publication date
AU2022401939A1 (en) 2024-05-30
TW202330032A (zh) 2023-08-01
CN118175993A (zh) 2024-06-11
WO2023098694A1 (zh) 2023-06-08
US20250011411A1 (en) 2025-01-09
EP4434517A1 (en) 2024-09-25
EP4434517A4 (en) 2025-06-25
JP2024543931A (ja) 2024-11-26

Similar Documents

Publication Publication Date Title
US11612659B2 (en) Anti-CD40 antibody formulation delivery device
BR112021008288A2 (pt) composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma
CN109952093B (zh) 一种sost抗体药物组合物及其用途
JP2026048838A (ja) 高濃度抗ｃ５抗体配合物
US20230173069A1 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
JP2018531980A (ja) 抗ｄ因子抗体製剤
TW201902518A (zh) 一種含c-Met抗體藥物偶聯物的醫藥組成物及其用途
WO2022000046A1 (en) High concentration formulation of factor xii antigen binding proteins
US20250011411A1 (en) Anti-SOST Antibody Pharmaceutical Composition and Use Thereof
US20240409631A1 (en) Aqueous formulations of an anti-cd22 antibody and uses thereof
JP2025519600A (ja) 抗ｉｇｆ－１ｒ抗体組成物
CN115227813A (zh) 一种含抗Abeta抗体的药物组合物
CN117679504A (zh) 一种抗Claudin18.2抗体药物组合物及其用途
CN115867579A (zh) 乐维利单抗的水性药用组合物及其用途
JP2021088548A (ja) 安定な水性抗体製剤
RU2779430C2 (ru) Фармацевтическая композиция, содержащая антитело к sost, и ее применения
TW202541841A (zh) 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法
HK40009387B (en) Sost antibody pharmaceutical composition and uses thereof
HK40009387A (en) Sost antibody pharmaceutical composition and uses thereof
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
CN118078988A (zh) 包含靶向il-17a的抗体药物组合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024